Evidence map›Paper›PMID 26464651›Full record

ArticleInternational journal of clinical and experimental pathology2015

Expression of protein TARBP1 in human hepatocellular carcinoma and its prognostic significance.

Jingmei Ye, Jiani Wang, Li Tan, Shaojiang Yang, Lihua Xu, Xiaohong Wu, Huaifu Deng, Huo Tan

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Identification of Hub Genes in Hepatocellular Carcinoma Related to Progression and Prognosis by Weighted Gene Co-Expression Network Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Jingmei YeDepartment of Blood Transfusion, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510230, China.
Jiani WangBreast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou 510630, China.
Li TanDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510230, China.
Shaojiang YangDepartment of Hematology, The First People's Hospital of Foshan Foshan 528000, China.
Lihua XuDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510230, China.
Xiaohong WuDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510230, China.
Huaifu DengPET/CT Center, Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510230, China.
Huo TanDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University Guangzhou 510230, China.
First Affiliated Hospital of Guangzhou Medical University · CNFirst People's Hospital of Foshan · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to analyze the expression of TARBP1 and its clinical significance in hepatocellular carcinoma (HCC). MATERIALS AND

methods90 patients with primary hepatocellular carcinoma were included in this study. The tumor and paired adjacent non-tumor tissues were collected. TARBP1 expression was assessed by quantitative real-time polymerase chain reaction and immunohistochemistry. Associations of TARBP1 expression with the clinicopathological features were analyzed, and prognosis of HCC patients was evaluated.

resultsThe result show the expression of TARBP1 mRNA in liver cancer tissues were higher than in the adjacent normal liver tissues in 10 paired samples (P=0.0015). Compared with adjacent normal liver tissues, overexpression of TARBP1 was detected in 61.1% (55/90) HCC patients. TARBP1 expression was associated with the AJCC tumor stage (P=0.004) and clinical stage (P=0.005), and decreased overall survival (P=0.002). In multivariate analysis, TARBP1 expression was an independent prognostic factor for overall survival (Hazard ratio [HR]=2.773, 95% confidence interval [CI] 1.542-4.985; P=0.019).

conclusionsTARBP1 is up-regulated in HCC, and the expression of TARBP1 was associated with the pathological grading and clinical stage. TARBP1 maybe is an independent prognostic marker of HCC patients.

Indexed as

Up-RegulationAdultAgedAged, 80 and overCarcinoma, HepatocellularFemaleHumansLiverLiver NeoplasmsMaleMiddle AgedNuclear ProteinsPrognosisRNA-Binding ProteinsTrans-Activation Responsive RNA-Binding ProteinNuclear ProteinsRNA-Binding ProteinsTARBP1 protein, humanTrans-Activation Responsive RNA-Binding ProteinHepatocellular carcinoma-TARBP1- prognosis

Identifiers

PMID26464651
PMCPMC4583883
OpenAlexW2415363337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.